Caring for Patients at Every Stage: Standard of Care and Future Approaches
Release Date: April 10, 2019
Expiration Date: April 10, 2020
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity will address several practice-related issues regarding the management of patients with multiple myeloma. Nurses who provide direct patient care may encounter many different hematologic malignancies throughout their day. Consequently, they may face the challenge of remaining current on treatment and monitoring approaches for multiple myeloma at all stages of the disease, from the newly diagnosed patient to the relapsed/refractory patient. In this text-based activity, four expert faulty provide the background and insights needed to properly manage this patient population.
This activity is designed for nurses in the community setting who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast emerging drug classes for treating newly diagnosed multiple myeloma and outline the proper sequencing of therapies
- Detail standard of care for transplant-eligible candidates and outline the current role of transplant for the treatment of multiple myeloma
- Describe current and emerging therapies available for relapsed/refractory multiple myeloma
- Identify the efficacy and safety of emerging CAR T-cell therapies for the treatment of multiple myeloma
Emerging Approaches to the Treatment of Newly Diagnosed Multiple Myeloma – Keith Stewart, MB, ChB, MBA
Focus on Induction Regimens for Transplant-eligible Patients with Multiple Myeloma – Sergio A. Giralt, MD, FACP
Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond – Sagar Lonial, MD, FACP
Novel Therapeutic Approaches in Multiple Myeloma: The Future of CAR T-Cells – Noopur Raje, MD
Instructions for Participation and Credit
This activity is eligible for credit through April 10, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.
Sergio A. Giralt, MD, FACP
Professor of Medicine
Weill Cornell Medical College
Chief Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Chief Attending Physician of the Adult Bone Marrow Transplant Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America. Dr. Giralt previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research, the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and is past president of ASBMT.
Dr. Giralt’s clinical and research activities include stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.
Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.
Keith Stewart, MB, ChB, MBA
Professor of Cancer Research
Director, Center for Individualized Medicine
Dr. Keith Stewart is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic. In addition, he serves as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine, and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s current responsibilities at Mayo Clinic relate to the application of genomics to human health across the spectrum of discovery, translation, and application to clinical practice. He has served in several leadership roles across both research and clinical practice at Mayo Clinic, including as Dean for Research in Arizona, and as a member of the Arizona Executive Operations Team and Clinical Practice Committees.
Dr. Stewart has served on multiple boards for both non-profit and commercial organizations, most recently as a non-executive board member with Genomics England, Oncospire Inc. and OneOme Inc. He has more than 25 years of sustained national funding for a laboratory research program. He has authored more than 300 journal articles and other written publications, and has served as an associate editor of Blood and ASH Clinical News. Dr. Stewart’s research interest is in the genomics and biology of myeloma and he has led numerous clinical trials of new drugs for this blood cancer.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-010-101
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sergio Giralt has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., Jazz Pharmaceuticals plc, Kite Pharma, Novartis AG, and Sanofi.
Dr. Sagar Lonial has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology.
Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Takeda Oncology.
Dr. Keith Stewart has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Seattle Genetics, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager; Andrea Mathis, Project Manager; and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.